These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11500820)

  • 21. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants.
    Mulholland EK; Byass P; Campbell H; Fritzell B; Greenwood AM; Todd J; Greenwood BM
    Ann Trop Paediatr; 1994; 14(3):183-8. PubMed ID: 7825990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants.
    Mulholland EK; Ahonkhai VI; Greenwood AM; Jonas LC; Lukacs LJ; Mink CM; Staub JM; Todd J; Vella PP; Greenwood BM
    Pediatr Infect Dis J; 1993 Aug; 12(8):632-7. PubMed ID: 8414774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants.
    Anderson EL; Decker MD; Englund JA; Edwards KM; Anderson P; McInnes P; Belshe RB
    JAMA; 1995 Mar; 273(11):849-53. PubMed ID: 7869554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
    Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
    Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differing serologic responses to an haemophilus influenzae type b polysaccharide-neisseria meningitidis outer membrane protein conjugate (PRP-OMPC) vaccine in australian aboriginal and caucasian infants - implications for disease epidemiology.
    Guthridge S; McIntyre P; Isaacs D; Hanlon M; Patel M
    Vaccine; 2000 May; 18(23):2584-91. PubMed ID: 10775792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of carrier proteins on vaccine-induced immune response.
    Knuf M; Kowalzik F; Kieninger D
    Vaccine; 2011 Jul; 29(31):4881-90. PubMed ID: 21549783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.
    Bröker M; Berti F; Schneider J; Vojtek I
    Vaccine; 2017 Jun; 35(25):3286-3294. PubMed ID: 28487056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.
    Santosham M; Wolff M; Reid R; Hohenboken M; Bateman M; Goepp J; Cortese M; Sack D; Hill J; Newcomer W
    N Engl J Med; 1991 Jun; 324(25):1767-72. PubMed ID: 1903846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 37. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease caused by Haemophilus influenzae type b in the immediate period after homologous immunization: immunologic investigation.
    Sood SK; Daum RS
    Pediatrics; 1990 Apr; 85(4 Pt 2):698-704. PubMed ID: 2107522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
    Qiao W; Ji S; Zhao Y; Hu T
    Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease.
    Molrine DC; George S; Tarbell N; Mauch P; Diller L; Neuberg D; Shamberger RC; Anderson EL; Phillips NR; Kinsella K; Ambrosino DM
    Ann Intern Med; 1995 Dec; 123(11):828-34. PubMed ID: 7486464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.